期刊
CLINICAL ONCOLOGY
卷 20, 期 6, 页码 401-416出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.clon.2008.04.003
关键词
drug therapy; radiotherapy; randomised controlled trials; review; systematic review; uterine cervical neoplasms
类别
资金
- MRC [MC_U122861323] Funding Source: UKRI
- Medical Research Council [MC_U122861323] Funding Source: researchfish
- Medical Research Council [MC_U122861323] Funding Source: Medline
In the past, women with early-stage cervical cancer have been treated with radical radiotherapy or radical surgery, and women with locally advanced disease with radical radiotherapy, each offering a good chance of cure. Numerous trials have investigated whether giving cytotoxic chemotherapy alongside radiotherapy or before local treatment could augment the established benefits of these therapies. There is a strong basis for the use platinum-based chemoradiotherapy, the current standard of care, but little convincing evidence as to the therapeutic benefits of using concomitant hydroxyurea. Chemoradiotherapy based on other non-platinum agents may offer alternatives. The effect of chemoradiotherapy seems to vary according to the stage of disease, but all types of women benefit. Neoadjuvant chemotherapy before radiotherapy could jeopardise survival and should be avoided unless perhaps a 'quick', dose-intense regimen is used. Neoadjuvant chemotherapy before surgery may be beneficial, but the approach will remain controversial until it is tested against platinum-based chemo radiotherapy. Future studies many include combinations of other cytotoxics, such as topotecan, with cisplatin-based concomitant chemoradiotherapy or the addition of agents targeted against specific receptors, such as epidermal growth factor receptor.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据